Race and breast cancer survival by intrinsic subtype based on PAM50 gene expression

被引:0
|
作者
Candyce H. Kroenke
Carol Sweeney
Marilyn L. Kwan
Charles P. Quesenberry
Erin K. Weltzien
Laurel A. Habel
Adrienne Castillo
Phillip S. Bernard
Rachel E. Factor
Lawrence H. Kushi
Bette J. Caan
机构
[1] Kaiser Permanente Northern California,Division of Research
[2] University of Utah,Division of Epidemiology
来源
关键词
Race; Ethnicity; Breast cancer survival; Breast cancer mortality; Gene expression; Molecular subtype; Intrinsic subtype; PAM50;
D O I
暂无
中图分类号
学科分类号
摘要
To evaluate whether differences in PAM50 breast cancer (BC) intrinsic (Luminal A, Luminal B, Basal-like, and HER2-enriched) subtypes help explain the Black–White BC survival disparity. Utilizing a stratified case-cohort design, this study included 1,635 women from the Pathways and Life After Cancer Epidemiology cohorts, selecting women with tumors based upon IHC classification, recurrences, and deaths.One millimeter punches were obtained from tumor tissue, and expression of the PAM50 genes for molecular subtype was determined by RT-qPCR of extracted RNA. Cox proportional hazards models were used to analyze associations between race and BC outcomes, adjusted for PAM50 BC subtype. All tests of statistical significance were two-sided. Black women had a higher prevalence of the Basal-like BC subtype. Adjusted for potential confounding variables and disease characteristics at diagnosis, Black women had higher risks of recurrence (HR 1.65, 95 % CI 1.06–2.57) and breast cancer-specific mortality (HR 1.71, 95 % CI 1.02–2.86) than White women, but adjusting further for subtype did not attenuate survival disparities. By contrast, Hispanic women had a lower risk of recurrence (HR 0.54, 95 % CI 0.30–0.96) than Whites. Among those with the Basal-like subtype, Black women had a similar recurrence risk as women in other race groups but a higher recurrence risk for all other subtypes. Hispanic women had a lower recurrence risk within each subtype, though associations were not significant, given limited power. Although Black women had a higher risk of the Basal-like subtype, which has poor prognosis, this did not explain the Black–White BC survival disparity.
引用
收藏
页码:689 / 699
页数:10
相关论文
共 50 条
  • [21] Breast cancer PAM50 subtypes: Correlation
    Picornell, A. C.
    Echavarria Diaz-Guardamino, I.
    Alvarez Castillo, E. L.
    Lopez-Tarruella Cobo, S.
    Jerez, Y.
    Hoadley, K.
    Parker, J.
    del Monte-Millan, M.
    Ramos Medina, R.
    Gayarre, J.
    Ocana, I.
    Cebollero, M.
    Massarrah, T.
    Moreno Anton, F.
    Garcia-Saenz, J. A.
    Gomez Moreno, H.
    Ballesteros Garcia, A. I.
    Ruiz Borrego, M.
    Perou, C.
    Martin Jimenez, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [22] Research-based PAM50 signature and long-term breast cancer survival
    Minya Pu
    Karen Messer
    Sherri R. Davies
    Tammi L. Vickery
    Emily Pittman
    Barbara A. Parker
    Matthew J. Ellis
    Shirley W. Flatt
    Catherine R. Marinac
    Sandahl H. Nelson
    Elaine R. Mardis
    John P. Pierce
    Loki Natarajan
    Breast Cancer Research and Treatment, 2020, 179 : 197 - 206
  • [23] Prediction of lung cancer survival by genes in the PAM50 breast cancer panel.
    Siegfried, Jill M.
    Lin, Yan
    Dacic, Sanja
    Diergaarde, Brenda
    Stabile, Laura P.
    Lin, Hui-Min
    Romkes, Marjorie
    CLINICAL CANCER RESEARCH, 2014, 20
  • [24] Research-based PAM50 signature and long-term breast cancer survival
    Pu, Minya
    Messer, Karen
    Davies, Sherri R.
    Vickery, Tammi L.
    Pittman, Emily
    Parker, Barbara A.
    Ellis, Matthew J.
    Flatt, Shirley W.
    Marinac, Catherine R.
    Nelson, Sandahl H.
    Mardis, Elaine R.
    Pierce, John P.
    Natarajan, Loki
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 179 (01) : 197 - 206
  • [25] Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes
    Santonja, Angela
    Sanchez-Munoz, Alfonso
    Fernandez, Yessica Plata
    Miramon, Jose
    Zarcos, Irene
    Perez, Casilda Llacer
    de Luque, Vanessa
    Fernandez-Sousa, Cristina
    Jerez, Jose Manuel
    Alvarez, Martina
    Vicioso, Luis
    Alba, Emilio
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] Race and age differences in PAM50 biomarker status in the Carolina breast cancer study
    Troester, M. A.
    Sun, X.
    Allott, E. H.
    Kit, C-K
    Thorne, L.
    Mathews, M.
    Cohen, S. M.
    Geradts, J.
    Kirk, E.
    Li, Y.
    Hu, Z.
    Robinson, W.
    Hoadley, K. A.
    Reeder-Hayes, K.
    Earp, S.
    Olshan, A. F.
    Carey, L. A.
    Perou, C. M.
    CANCER RESEARCH, 2017, 77
  • [27] Association between PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients
    Jorgensen, C. L. T.
    Nielsen, T. O.
    Bjerre, K. D.
    Liu, S.
    Wallden, B.
    Balslev, E.
    Nielsen, D. L.
    Ejlertsen, B.
    CANCER RESEARCH, 2012, 72
  • [28] Molecular subclassification of NCI PDMR breast cancer models using PAM50 gene expression signature
    Wu, Peter I.
    Dutko, Lindsay
    Jiwani, Shahanawaz
    Chen, Li
    Das, Biswajit
    Chang, Ting-Chia
    Evrard, Yvonne A.
    Karlovich, Chris A.
    Chapman, Alyssa
    Fullmer, Brandie
    Hayes, Ashley
    Thornton, Ruth
    Nair, Nikitha
    Benauer, Kelly
    Rivera, Gloryvee
    Forbes, Thomas
    Carter, John
    Borgel, Suzanne
    Miner, Tiffanie
    McGlynn, Chelsea
    Mills, Justine
    Uzelac, Shannon
    Shearer, Tia
    Hicks, Lauren
    Norris, Michelle
    Border, Carley
    Alcoser, Sergio
    Walsh, Thomas
    Mullendore, Michael
    Eugeni, Michelle
    Newton, Dianne
    Hollingshead, Melinda G.
    Williams, P. M.
    Doroshow, James H.
    CANCER RESEARCH, 2023, 83 (07)
  • [29] Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
    Schettini, Francesco
    Chic, Nuria
    Braso-Maristany, Fara
    Pare, Laia
    Pascual, Tomas
    Conte, Benedetta
    Martinez-Saez, Olga
    Adamo, Barbara
    Vidal, Maria
    Barnadas, Esther
    Fernandez-Martinez, Aranzazu
    Gonzalez-Farre, Blanca
    Sanfeliu, Esther
    Cejalvo, Juan Miguel
    Perrone, Giuseppe
    Sabarese, Giovanna
    Zalfa, Francesca
    Peg, Vicente
    Fasani, Roberta
    Villagrasa, Patricia
    Gavila, Joaquin
    Barrios, Carlos H.
    Lluch, Ana
    Martin, Miguel
    Locci, Mariavittoria
    De Placido, Sabino
    Prat, Aleix
    NPJ BREAST CANCER, 2021, 7 (01)
  • [30] Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
    Francesco Schettini
    Nuria Chic
    Fara Brasó-Maristany
    Laia Paré
    Tomás Pascual
    Benedetta Conte
    Olga Martínez-Sáez
    Barbara Adamo
    Maria Vidal
    Esther Barnadas
    Aranzazu Fernández-Martinez
    Blanca González-Farre
    Esther Sanfeliu
    Juan Miguel Cejalvo
    Giuseppe Perrone
    Giovanna Sabarese
    Francesca Zalfa
    Vicente Peg
    Roberta Fasani
    Patricia Villagrasa
    Joaquín Gavilá
    Carlos H. Barrios
    Ana Lluch
    Miguel Martín
    Mariavittoria Locci
    Sabino De Placido
    Aleix Prat
    npj Breast Cancer, 7